412 A Phase 3, Lansoprazole-Controlled, Long-Term Extension Study to Evaluate the Safety and Efficacy of Vonoprazan (10 mg or 20 mg) for Prevention of Recurrent Peptic Ulcers During Long-Term Therapy With Non-Steroidal Anti-Inflammatory Drug (NSAID)

2015 ◽  
Vol 148 (4) ◽  
pp. S-88-S-89 ◽  
Author(s):  
Yuji Mizokami ◽  
Kazunori Oda ◽  
Kojiro Saito ◽  
Nobuo Funao ◽  
Akira Nishimura ◽  
...  
Keyword(s):  
Extension Study ◽  
Term Therapy ◽  
Peptic Ulcers ◽  
Phase 3 ◽  
Safety And Efficacy ◽  
Inflammatory Drug ◽  
Anti Inflammatory ◽  
Long Term Therapy

scholarly journals Long-term therapy with non-steroidal anti-inflammatory drugs for axial spondyloarthritis: focus on changes in liver function

2021 ◽  
pp. 152-157
Author(s):  
A. P. Rebrov ◽  
A. V. Aparkina ◽  
E. V. Kchondkaryan
Keyword(s):  
Liver Function ◽  
Liver Enzymes ◽  
Genetically Engineered ◽  
Term Therapy ◽  
Acute Liver Damage ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Long Term Therapy

The purpose of the study is to analyze the state of liver function in patients with spondyloarthritis taking non-steroidal anti-inflammatory drugs continuously for 24 months. Materials and methods of the study include 198 patients with spondyloarthritis. The prospective study involved 36 patients with spondyloarthritis who took non-steroidal anti-inflammatory drugs (NSAIDs) prescribed by a physician in the community for 24 months. The level of liver enzymes in blood serum at admission and in dynamics was studied. The increase of liver enzymes was detected in 12 (6.06%) of 198 patients with spondyloarthritis. Among them 6 (50%) patients took methotrexate, 1 (8.33%) - genetically engineered drug, 2 (16.67%) patients-sulfasalazine and 3 (25%) - nonsteroidal anti - inflammatory drugs. 19.4% of patients were registered with a periodic increase of transaminase levels on the background of NSAIDs for the last 24 months. At the same time, no cases of acute liver damage or progressive deterioration of liver function requiring discontinuation of therapy were recorded during the entire follow-up period.

scholarly journals Correction to: Safety and efficacy of guanfacine extended-release in adults with attention-deficit/hyperactivity disorder: an open-label, long-term, phase 3 extension study

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Akira Iwanami ◽  
Kazuhiko Saito ◽  
Masakazu Fujiwara ◽  
Daiki Okutsu ◽  
Hironobu Ichikawa
Keyword(s):  
Attention Deficit Hyperactivity Disorder ◽  
Attention Deficit ◽  
Extended Release ◽  
Extension Study ◽  
Open Label ◽  
Phase 3 ◽  
Safety And Efficacy ◽  
Hyperactivity Disorder

An amendment to this paper has been published and can be accessed via the original article.

scholarly journals Serum myristic fatty acid negatively correlates with anti-inflammatory adiponectin/leptin ratio in obese adolescents: effects of long- term therapy

2017 ◽  
Vol 40 (A) ◽  
pp. 537-554 ◽  
Author(s):  
Aline de Piano-Ganen ◽  
Deborah Cristina Landi Masquio ◽  
Ana R. Dâmaso ◽  
Lila Missae Oyama ◽  
Debora Estadella ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Term Therapy ◽  
Obese Adolescents ◽  
Anti Inflammatory ◽  
Long Term Therapy

Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp- CFTR mutation: a phase 3, open-label extension study (PERSIST)

2014 ◽  
Vol 2 (11) ◽  
pp. 902-910 ◽  
Author(s):  
Edward F McKone ◽  
Drucy Borowitz ◽  
Pavel Drevinek ◽  
Matthias Griese ◽  
Michael W Konstan ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Extension Study ◽  
Open Label ◽  
Phase 3 ◽  
Safety And Efficacy ◽  
Open Label Extension
Sign in / Sign up

Export Citation Format

Share Document